Grupo Espanol De Tumores Neuroendocrinos

This study tested the drug cabozantinib in 41 adults with advanced differentiated thyroid cancer that no longer responds to radioactive iodine treatment. Participants took a 60 mg pill daily until their cancer worsened or side effects became too severe. The main goal was to under…

This study tested whether adding the drug axitinib to standard sandostatin LAR therapy could slow tumor growth in 256 people with advanced neuroendocrine tumors (G1-G2) that started outside the pancreas. Participants received either the combination or sandostatin plus a placebo. …

This study looked back at the medical records of 19 Spanish patients with rare NTRK fusion cancers who received the targeted drug larotrectinib before it was widely available. The goal was to see how well the drug worked in real-world settings. The study did not involve new treat…